NetworkNewsBreaks – Cytori Therapeutics, Inc. (NASDAQ: CYTX) Shares Plummet to New Low on Disappointing STAR Trial Results
Shares of Cytori Therapeutics (NASDAQ: CYTX) sunk to a new 52-week low of $0.45 following the company’s release of top-line preliminary data from its pivotal STAR trial of Habeo™ Cell Therapy in patients with scleroderma. Results show that statistical significance was not achieved in the primary endpoint, Cochin Hand Function Score (CHFS), or the secondary endpoint, Raynaud’s Condition Score. However, clinically meaningful efficacy trends were observed in both the efficacy endpoints. “We are disappointed that the study missed the primary and secondary endpoints. However, we are very encouraged by the trends toward improved hand function and scleroderma-related health status in…